The Foundation for Vaccine Research - Working to Secure Our Children's Future
Photo: Clive Gray, Cape Town

Our website is being redesigned to improve performance and readability on all devices. It will relaunch in full shortly.

9 January 2017

Triple gene knockout revives prospects for a live-attenuated malaria vaccine

Results of a phase 1 study of a genetically-attenuated malaria vaccine published in Science and Translational Medicine showed that the vaccine was safe and well tolerated, opening up a third potential pathway to the development of a whole parasite vaccine via the creation of live-attenuated parasite strains using gene deletions.

The triple gene knockout worked as designed in its first human clinical trial, causing neither malaria nor serious safety problems in the 10 people who volunteered to be infected by mosquitoes. It also stimulated an immune response that holds out promise of a more protective vaccine than the single malaria candidate vaccine, RTS,S, now in pilot roll-out studies.

The live-attenuated parasite vaccine was created by scientists at the Seattle-based Center for Infectious Disease Research (CIDR), which pioneered the creation of genetically-attenuated Plasmodium parasites. The phase 1 study was conducted by scientists at CIDR and Fred Hutchinson Cancer Research Center, with support from U.S. Army.

Read Science and Translational Medicine paper

Read Science news article

Read more

London School of Hygiene & Tropical MedicineMalaria sporozoites burst from an oocyst on the gut wall of the mosquito. They will migrate to the mosquito's salivary glands, and then infect humans when the mosquito feeds. The malaria parasite later infects human red blood cells, causing anemia, cyclic fevers and even death.

Malaria is caused by the Plasmodium falciparum parasite and spreads to humans through the bite of an infectious mosquito. With 5,300 genes and a life cycle that involves multiple stages in humans and mosquitoes, the Plasmodium parasite is far more complex than disease-causing viruses, complicating efforts to develop a vaccine against it.

Transmission occurs through the bite of an infected female Anopheles mosquito and the resulting deposition of a relatively small number of Plasmodium sporozoites into the skin of the host. Sporozoites traverse numerous cells in the skin before entering the bloodstream and rapidly going on to infect hepatocytes. The sporozoites then transform into liver stages of the parasite, which go on to replicate within the liver without causing symptoms, generating tens of thousands of new forms of the parasite that exit the liver and infect red blood cells. Infection of red blood cells is cyclical and rapidly expands the parasite population, causing the classic fever, chills, headaches and other malaria-associated symptoms that can lead to death in babies, young children and adults. Studies conducted in a mouse model with a human liver suggest that effectively targeting the pre-erythrocytic sporozoite and liver stages by vaccination could cripple the parasite, preventing disease and death and, as a bonus, prevent onward transmission.

close

The gene knockout concept

The notion of using genetically-attenuated malaria parasites as a vaccine to prime the immune system has long intrigued scientists and has been extensively explored in rodent malaria models. The discovery of numerous gene knockouts that arrest parasite development at critical points during liver infection in the mouse led to the creation of the first dual gene deletion strain of Plasmodium falciparum. Of all Plasmodium species that infect humans and animals, P. falciparum is the deadliest human malaria parasite. It is responsible for 75% of malaria cases – and nearly all deaths – in sub-Saharan Africa.

The deletion of two genes in P. falciparum, Pf. p52 and Pf. 36, expressed in the “pre-erythrocytic stage” of the parasite’s life cycle had been shown in an earlier phase 1 study to severely cripple the parasite but did not achieve complete attenuation in human infection. The two genes regulate sporozoite infectivity for mammalian hosts before red blood cells are infected, including factors that are critical for parasite liver infection and liver stage growth.

To see if the deletion of a third gene expressed during the same stage of the parasite’s life cycle could achieve full attenuation, scientists went on to create a triple gene deletion strain of P. falciparum by knocking out an additional gene in the SAP1 locus shown to be essential for successful liver stage infection in rodent malaria parasites.

Results from a second phase 1 study conducted in 2015 and reported last week in Science and Translational Medicine showed that the addition of a third gene deletion maintained immunogenicity and achieved full attenuation. The triple gene knockout permanently and uniformly crippled the complex malaria parasite so that it cannot go on to infect red blood cells and cause disease and, instead, effectively primes the immune system, reviving hopes that a genetically-attenuated parasite vaccine is a feasible alternative.

RTS,S subunit vaccine

The most clinically advanced malaria vaccine candidate to date is GSK’s subunit (whole protein) vaccine, RTS,S/AS01, which targets the host immune response through production of antibodies to a major P. falciparum sporozoite surface protein, the circumsporozoite protein (CSP), which mediates protection by preventing infectious sporozoites from reaching the liver. A large phase 3 clinical trial with RTS,S showed some efficacy against clinical malaria infection. However, such protection was short-lived and well below the goal of 75% set forth by the WHO, even after four immunizations. Nevertheless, the data that partial pre-erythrocytic immunity can reduce clinical malaria episodes were the first evidence for any efficacy by a malaria vaccine, raising hopes that generating a higher degree of sterilizing pre-erythrocytic immunity by vaccination could not only prevent disease and death but also contribute to elimination of malaria.

Whole sporozoite vaccines

Numerous pre-clinical and clinical studies have demonstrated that immunization with whole malaria sporozoite vaccines can confer complete, sterilizing immunity against malaria infection. Such vaccines likely mediate protection by generating a high frequency of T cell responses in the liver. Moreover, an important feature of whole sporozoite vaccines is their ability to generate responses to multiple antigens, providing breadth of immunity. There are currently three approaches using whole sporozoite vaccines.

Radiation-attenuated sporozoites

The most widely-studied immunization strategy is with radiation-attenuated sporozoites, in which parasites are subjected to random irradiation-induced DNA damage, thereby preventing parasite replication in the liver. In a number of clinical studies in the U.S. and Africa, radiation-attenuated sporozoites have been shown to be very safe and well tolerated. Moreover, durable protection has been observed up to 1 year following 3 immunizations administered by direct venous inoculation in malaria-naïve adults. Based on these data, there are ongoing studies in Africa to determine if this vaccine approach confers sterilizing protection in infants and adults.

Concurrent administration of antimalarial drugs

A second strategy is immunization with live, infectious sporozoites and the concurrent administration of antimalarial drugs, which allows for completion of liver infection and eliminates asexual parasites once they initiate replication within red blood cells. This method requires about 20-fold fewer sporozoites to induce complete protection but is limited by the need to provide continuous antimalarial drug cover during immunization. Ongoing studies using drug therapy that can be administered only at the time of immunization with the live sporozoites will determine if this is safe and the vaccine remains protective.

Genetically-attenuated sporozoites

The third strategy, immunization with live sporozoites that can self-attenuate in vivo, provides potentially the optimal approach for safety, efficacy and efficiency. Accordingly, scientists in Seattle developed a way to weaken the live malaria parasite in vivo by knocking out three genes that the organism needs to replicate in the human liver and re-emerge in the bloodstream to cause illness. The use of a genetically-attenuated parasite marks the first time that genetic engineering has been used to combat any parasitic disease. From a safety standpoint, this live-infection vaccine approach would self-attenuate in the liver and not require any drug treatment. In terms of vaccine efficacy, a critical aspect is where in the liver the live sporozoites attenuate. Pre-clinical data suggest that if the attenuation occurs late in the liver stage, protection is improved. In this regard, it would mimic the efficiency of the live-infection vaccine without the need for drug treatment.

The Seattle study

In the phase 1 triple gene knockout trial, the safety and immunogenicity of the genetically-engineered sporozoites were tested in 10 human volunteers using infected mosquito bites with a single exposure consisting of 150 to 200 bites per subject. All subjects remained blood stage-negative and developed inhibitory antibodies to sporozoites.

The phase 1 study focused on safety and immune responses. It did not directly test whether the immune responses that were elicited actually protected against malaria infection. Now that the approach has been shown to be safe, the next step will be a full efficacy evaluation in a controlled human challenge trial planned for later this year. The new trial will deliver the attenuated parasites to volunteers and then expose them to a strain of malaria that is easily diagnosed and responds to conventional antimalarial treatment.

For the moment, the triple gene knockout sporozoites can only be produced in the salivary glands of mosquitoes. So in the trial, each of the 10 volunteers placed their arms over a net-covered cup of mosquitoes and endured 150 to 200 bites in one 10-minute session.

Challenges ahead

Once safety and protective efficacy is established, the next critical step is to isolate the sporozoites from the mosquito so they can be enumerated and frozen for use in a vaccine study, an approach that has been done for irradiated sporozoites. The ultimate goal will be to perfect a manufacturing approach so the sporozoites can be grown to scale in vitro without the mosquito. There is existing data for doing this but it will require refinement. Developing a better – and more comfortable – delivery method will be a high priority. Down the road, the large-scale production of genetically-attenuated sporoziotes may prove to be an even greater challenge since no one has yet found a way to mass produce sporozoites in the quantities that would be needed for a mass vaccination campaign.

In the meantime, there are few places in the world that can do the controlled human challenge trial planned for later this year. CIDR’s Human Challenge Center, which is based at the Fred Hutchinson Cancer Research Center in Seattle and run by CIDR, is one of only four places in the U.S. – and the only non-military center – with an “insectary” for breeding malaria-carrying mosquitoes. The Hutch also conducts malaria human challenge trials that deliver malaria sporozoites – the infectious form of the parasite ordinarily introduced into human blood by a mosquito’s bite – via direct venous inoculation.

This approach developed by Sanaria, a biotech in Rockville, MD, could offer a more practical and more scalable delivery method down the road. The biotech has also developed the technology to grow and harvest large quantities of purified Plasmodium sporozoites and formulate them for use in vaccines for human use, as well as genetically-attenuated sporozoites as immunogen to be used in live-attenuated vaccines.

Read Science and Translational Medicine paper

Download pdf copy

Read Science news article

22 December 2016

Ebola experimental vaccine provides 100% protection, study shows

Final results from the Guinea "ring vaccination", open-label, cluster-randomized trial published in The Lancet show an rVSV-vectored vaccine to be highly effective in preventing Ebola infection. Of nearly 6,000 volunteers vaccinated with the vaccine, all were free of the virus 10 days later. In a group of the same size not vaccinated, 23 later developed Ebola disease.

The experimental vaccine, VSV-ZEBOV, is a recombinant, replication-competent vesicular stomatitis virus-vectored vaccine expressing a surface glycoprotein of Zaire Ebolavirus. Originally developed in Canada but now owned and manufactured by Merck, the vaccine is currently being fast-tracked for approval by U.S. and European regulatory agencies.

The Guinea trial, dubbed “Ebola Ça Suffit!” – which translates as “Ebola, enough already!” – was conducted by the World Health Organization in cooperation with the Guinea Ministry of Health, with financial support from the Wellcome Trust, Médecins Sans Frontières, the Norwegian Ministry of Foreign Affairs, and the Canadian Government.

There are multiple strains of Ebolavirus, and this vaccine covers the Zaire group and offers cross-protection for similar strains in this group, according to the WHO. But it doesn't confer protection from four other strains of Ebolavirus known to cause disease in humans: Sudan Ebolavirus, Taï Forest Ebolavirus (formerly Côte d'Ivoire Ebolavirus), and Bundibugyo virus (Bundibugyo Ebolavirus), nor from the related, and lethal, Marburg virus.

The rVSV-EBOV vaccine is expected to be available by 2018, if not before. Spurred by the success of this vaccine, work developing vaccines for the four other Ebolavirus strains will hopefully accelerate, as well as for Marburg virus.

Read Lancet paper

Read WHO news release

Health workers wearing protective gear gesture at the Nongo Ebola treatment center in Conakry, one of multiple sites for the rVSV-ZEBOV vaccine trial, which was conducted in the communities of Conakry and eight surrounding prefectures in the Basse-Guinée region of Guinea, and in Tomkolili and Bombali in Sierra Leone.

15 December 2016

Obama signs 21st Century Cures Act

Paying tribute to both bipartisanship and his vice president, Joe Biden – who was galvanized by his own son’s death to change the way the United States combats cancer – President Obama this week signed a landmark $6.3 billion bill to boost spending for medical research, speed the development and approval of experimental treatments, and overhaul federal policy on mental health.

Two years in the making, the bipartisan measure was approved in the U.S. Senate by an overwhelming 94-5 vote last week after passing the House of Representatives by a similar margin. The bill provides an infusion of $4.8 billion for the NIH for biomedical research, including a hefty $1.8 billion for cancer research, a part of the bill that was renamed the “Beau Biden Cancer Moonshot” by lawmakers in honor of the vice president’s son who died of a brain tumor. Of the balance, $500 million was set aside for the FDA to help speed the approval of drugs, with a further $1 billion in grants destined for states to battle the opioid crisis and address mental health challenges.

While vaccines are not included in the bill, the legislation should provide encouragement to advocates of increased U.S. investments in vaccine R&D by showing how bipartisan support can be mobilized to address the funding chasm that is impeding the development of critically needed new vaccines.

Read more

Surrounded by advocates and lawmakers, President Obama signs the 21st Century Cures Act into law.

"The Cures Act is a rare example of a concerted bipartisan effort to secure increased funding for promising areas of biomedical research with the potential to change the lives of thousands of Americans. While there is no money in it for vaccine research, the Act could serve as a model for bipartisan collaboration on an initiative to address the funding chasm that is impeding the development of urgently needed, life-saving vaccines for which there is no obvious market potential."

Prof. Adel A. Mahmoud, FVR Board Director
Department of Molecular Biology and
Woodrow Wilson School of Public and International Affairs
Princeton University
Former President, Merck Vaccines

14 December 2016

GSK opens new global vaccines R&D hub in Rockville, MD

Seeking to “walk the talk” with global biopreparedness efforts, GlaxoSmithKline yesterday cut the ribbon on its sparkling new Rockville, Maryland, vaccines R&D hub, welcoming research partners to its antibody-shaped campus outside of Washington, DC.

The new facility will serve as a dedicated location for the discovery and development of vaccines to prevent potential deadly disease outbreaks as GSK continues to push the conversation about creating a global network with other organizations and governments. The opening marks a another step forward in the development of the company’s proposed “Biopreparedness Organization.”

Confirming GSK’s ambitions in the field, CEO Andrew Witty said that the Rockville site can hopefully serve as a “node on a network of nodes” to create a much safer position for future threats after Ebola and Zika caught the scientific community off guard in recent years.

Read more

But getting buy-in from other stakeholders has been tough to attain. “Everybody we talked to loves it,” said Moncef Slaoui, GSK chairman of vaccines. “But we have been talking about it for two years and two months. It’s progressing very slowly because there are so many stakeholders involved. It’s a little frustrating, I must say, but we will continue and will be persistent.”

Witty said that in each recent outbreak, the global reaction has been "worse than the previous response.” The company is hoping to end that pattern with a move to "walk the talk" with a physical contribution to work in disease areas that might otherwise be neglected.

Rockville will be the home of GSK’s proposed “Biopreparedness Organization” (BPO), which the company conceives as a dedicated, permanent organization using a "no profit/no loss" model that will design and develop new vaccines against emerging viruses, bacteria and other pathogens that potentially pose a threat to global public health.

The new facility will employ 450 scientists and support staff – creating up to 200 new jobs – and house 12 critical vaccine development programs. In addition to biopreparedness, scientists at the site will conduct research in commercial vaccine areas. These include the further development and support for its candidate shingles vaccine, which was filed for FDA approval in October, as well as R&D programs for respiratory syncytial virus (RSV), Group B Streptococcus, and dengue which will be based at the site.

GSK acquired the Rockville site in 2012 when it bought Human Genome Sciences for $3 billion. The company says it will invest over $50 million in the next two years to continue to develop the site with latest state-of-the-art scientific research technology and equipment.

Rockville sits just outside Washington, DC in close proximity to the NIH, FDA, BARDA and other potential partners. The NIH recently signed on with the company to work on Zika. The Rockville site becomes one of three global vaccines R&D hubs for GSK, complementing the company’s existing global R&D centers in Rixensart, Belgium and in Siena, Italy.

Read GSK statement.

Read Fierce Vaccines article.

GSK commits $50 million to biopreparedness with opening of new state-of-the-art R&D center.

6 December 2016

International Vaccine Institute invests $34 million in Inovio’s MERS vaccine

New funding via the International Vaccine Institute (IVI) in Seoul, South Korea, made possible by a $34 million pledge to the institute by the Samsung Foundation, will allow the Pennsylvania biotech Inovio to expand development of its MERS vaccine, the only candidate against Middle East Respiratory Syndrome (MERS) now being testing in humans.

Co-developed in collaboration with Seoul-based GeneOne Life Science, Inovio’s DNA vaccine has been evaluated in mice, rhesus macaques and camels, inducing robust immune responses in all three species. Results showing 100% protection from a live virus challenge in a rhesus macaque non-human primate study supported moving the vaccine into the first Phase I human clinical trial of 75 healthy volunteers, being conducted in collaboration with the Walter Reed Army Institute of Research. With the trial fully enrolled and 75 subjects dosed, Inovio intends to report interim data in early 2017.

With success in the clinic, the company hopes to be in position to secure additional funding as well as work toward applying for emergency authorizations from regulators via the FDA’s “Animal Efficacy Rule.” Authorized by Congress in 2002 following the 9/11 attacks and concerns about bioterrorism, the “Animal Rule” provides a path to approval when human efficacy studies are not ethical or feasible. Through the pathway, companies may submit data from animal studies under certain circumstances to support their application.

Read Inovio statement.

Read Fierce Vaccines article.

MERS coronavirus particles. MERS-CoV is a zoonotic virus that has repeatedly entered the human population via contact with infected camels. Since MERS was first identified in Saudi Arabia in 2012, the virus has infected 1,900 people and caused 700 deaths, according to the World Health Organization. An outbreak in South Korea last year caused 38 deaths.

5 December 2016

Major HIV vaccine trial debuts in South Africa

Seven years after an HIV vaccine trial conducted in Thailand, RV144, demonstrated modest protection against HIV infection, the first participant was enrolled last week in HVTN 702, the largest HIV vaccine trial to be conducted since RV144, and the largest ever in South Africa. HVTN 702 is a phase 3/2b study and the only HIV vaccine efficacy trial currently taking place worldwide.

HVTN 702 follows HVTN 100, which was a smaller phase 1/2 trial conducted in South Africa to see if a modified two-vaccine regimen used in RV144 was safe and could produce stronger immunological responses. Interim results from HVTN 100 presented in July at the 21st International AIDS Conference in Durban (AIDS 2016), provided the green light for a phase 3 efficacy trial, HVTN 702, based on the modified regimen.

The two-vaccine regimen used in RV144 has been updated and adapted for use in HVTN 702. Both vaccines, Sanofi Pasteur’s canarypox-based vaccine, ALVAC-HIV, and GSK’s gp120 protein subunit vaccine, have been modified to be specific to HIV subtype C, the predominant HIV subtype circulating in Southern Africa. Additional modifications have been made designed to boost immune responses and produce longer lasting protection.

HVTN 702 will enroll 5,400 HIV-negative study participants between the ages of 18 and 35 at 15 sites in South Africa. Sponsored by NIAID, the $130 million study is scheduled to run through 2020 and marks another milestone in the global effort to develop an HIV vaccine.

See article in journal AIDS

Nkosiyazi Mncube, 23, was one of the first people to be vaccinated at the Medical Research Council’s clinic in Verulam near Durban on November 30 in KwaZulu-Natal. The clinic is one of 15 South African sites that will enroll 5,400 volunteers between 18 and 35.

26 September 2016

Congress approves $1.1 billion funding bill to combat Zika

More than eight months after the White House first asked for it, Congress has finally agreed on funding to help fight the Zika virus and study its effects. The stopgap measure signed by President Obama last week provides $1.1 billion to use in continuing work on the development of a Zika vaccine, as well as studies of the effects on unborn babies, adults and children. It will also help states control the mosquitoes that spread the virus.

The $1.1 billion is just over half what federal health agencies say they need, and the approval squeaked through just two days before the end of the fiscal year on September 30.

The NIH and CDC had almost run out of fresh money to fight Zika, even after the administration had pulled $589 million to keep Zika research going from other programs, including $500 million meant to help prevent another Ebola outbreak. The two agencies had to plunder emergency preparedness, cancer, vaccine and HIV programs for more cash.

In the end, the legislation directs $394 million for mosquito control and $397 million for vaccine development and better tests to diagnose Zika infections. Of the $152 million that NIAID will receive from the new funding for Zika projects, nearly all will go to vaccine work.

Read more

The Zika virus, which can cause microcephaly and other birth defects in newborns, is transmitted to humans via the bite of an infected Aedes sp. mosquito. Zika is a member of the same family of flaviviruses that cause yellow fever, West Nile, chikungunya and dengue fever.

2 September 2016

CEPI formally established

The Coalition for Epidemic Preparedness Innovations (CEPI) was formally established following a meeting of CEPI stakeholders at the Wellcome Trust in London on August 30. This announcement comes seven months after the World Economic Forum in Davos in January 2016 where the idea of a multinational partnership was born in a session devoted to vaccines and preparing for the next epidemic.

K. Vijay RagHavan, Secretary of the Indian Ministry of Science and Technology in Delhi, was elected CEPI chair, and Peter Piot, Director of the London School of Hygiene and Tropical Medicine, was elected CEPI vice-chair.

With this announcement, CEPI, which is as yet unfunded, is getting one step closer to the stage of preparing for a successful launch at the World Economic Forum in January 2017.

Congratulations to the FVR’s Stanley Plotkin, who co-chaired the science task force advising CEPI, and to the FVR’s Simon Wain-Hobson, who participated as a member of the science team.

See article in The Economist.

See article in Science.

Visit CEPI website.

Putting shots in the locker

"The formation of CEPI is the latest in a series of commendable initiatives post-Ebola to increase our preparedness ahead of the next pandemic. It is complementary to the proposed global vaccine development fund that is required to bridge the funding chasm that is impeding the development of vaccines for global diseases and infections that have been neglected for lack of a commercial market but which could save millions of lives.

We must not lose sight of the fact that we have a funding gap, and that resources will be needed on a massive scale to bridge this gap - both for pandemic preparedness and the endemic infections that continue unabated."

Prof. Simon Wain-Hobson, FVR Board Chair
Chief, Molecular Retrovirology
Institut Pasteur, Paris

16 May 2016

Industry leaders and policymakers express support for proposed fund in international forum organized by the Foundation and the National Academy of Medicine

"The stars are unusually aligned," said one senior vaccine industry expert. "We must seize this opportunity and not miss the occasion to act."

Industry leaders, government scientists and health officials, academicians and policymakers express support for the proposed global vaccine development fund and reform of the vaccine development process at a high-level, invitation-only international forum held May 16 at the National Academy of Sciences building in Washington DC.

Co-hosted and organized by the Foundation for Vaccine Research in partnership with the National Academy of Medicine, the forum drew 125 participants from the U.S. and around the world.

Key accomplishments

  • Broad consensus that the status quo is unacceptable and that reform of the vaccine development process is needed
  • Recognition that a persistent, identifiable, quantifiable financial gap is impeding the development of new vaccines
  • Agreement that substantial resources are needed to bridge this gap, and that industry alone cannot be expected to assume the investment risk
  • Acknowledgment that only governments have the resources on the scale required to bridge this gap and make this happen
  • Increased support for exploring financial mechanisms to leverage funding and mobilize new assets, including the establishment of a pooled funding mechanism
  • Recognition that the window of opportunity is fast closing

Next steps

  • Continue high-level consultations with stakeholders in the U.S. and globally
  • Coordinate with other bilateral and multilateral initiatives
  • Build political support to spur leadership, with special emphasis on U.S. government
  • Conduct a series of high-level private briefings for members of U.S. Congress and other decision makers
  • Prepare the groundwork for a major push by the next U.S. Administration
  • G7 summit in Italy 2017

Read more and download program

Forum poster
close

About the event

This international forum was held under the Chatham House Rule. The purpose was to build on the momentum generated by Ebola and Zika to focus attention on the need for comprehensive reform of the vaccine development process and how to accelerate the availability of new vaccines in advance of epidemics.

Topics for discussion included advances in science and technology, global research priorities, resource needs, financial gaps, resource allocation, mobilization of new assets, the merits and feasibility of different financing mechanisms that have been proposed to bridge these gaps, and the exploration of opportunities for greater collaboration and partnerships globally to maximize synergies and achieve mutual goals.

Event organizers

The Foundation for Vaccine Research
The National Academy of Medicine

Event chairs and co-chairs

Victor J. Dzau
Adel A.F. Mahmoud
Christian Bréchot
K. VijayRaghavan

Session co-chairs

Marie-Paule Kieny
Nicole Lurie
Julie Gerberding
Salim Abdool Karim
Simon Wain-Hobson

Speakers (in order of presentation)

Anthony Fauci
Stanley Plotkin
Anne Schuchat
Richard Hatchett
Ron Klain
Kenneth Frazier
Gary Nabel
David Weiner
Paul Stoffels
Tachi Yamada
Rino Rappuoli
Peter Piot
Mark Feinberg
Christopher Egerton-Warburton
Heather Deehan
Peter Hale

Event format and target audience

This event was designed for decision makers, policy makers and other leaders, bringing together 125 scientists, industry leaders, funders, public health officials and other experts from the U.S. and globally, with knowledge of the challenges facing vaccine developers.

Desired outcomes

It was hoped that a set of recommendations would emerge from the meeting that will help advance the global discussions currently underway on how to accelerate the development and availability of new vaccines. In addition, it was hoped that the meeting would generate increased support for exploring new mechanisms to leverage financing and mobilize new assets to speed vaccine development.  

Date and venue

Monday 16 May: Main event - all-day meeting from 8:00 am to 6:00 pm in the Lecture Room at the National Academy of Sciences building at 2101 Constitution Avenue NW, in Washington, DC.

Mix of topics

50% science, 50% policy. The agenda was designed to allow ample time for discussion at the end of each session, and a full hour for discussion in the last session of the day.

Event sponsors and strategic partners

The Bill & Melinda Gates Foundation
The Wellcome Trust

Download program

Feature Story

23 July 2015

Call for establishing a global vaccine development fund published in the New England Journal of Medicine.

Plotkin SA, Mahmoud AAF, Farrar J. Establishing a global vaccine development fund. N Engl J Med. 2015 Jul 23;373(4):297-300

See updated list of diseases and infections uncontrolled by vaccination.
 

Supplement to the N Engl J Med article

Audio interview with Dr. Stanley Plotkin, Emeritus Professor, University of Pennsylvania, and a Director, Foundation for Vaccine Research, on a strategy for stimulating and supporting global vaccine research. (9:21)

Listen
Download

close

Vaccine-Preventable Diseases and Infections and Targets Currently Uncontrolled by Vaccination. Updated August 21, 2015.*

Diseases and infections with commonly used vaccines

  • Diphtheria
  • Haemophilus influenzae type b
  • Hepatitis type A
  • Hepatitis type B
  • Human papillomavirus (HPV)
  • Influenza types A and B (seasonal)
  • Japanese encephalitis
  • Measles
  • Meningococcus
  • Mumps
  • Pertussis (whooping cough)
  • Polio
  • Pneumoccocus
  • Rabies
  • Rotavirus
  • Rubella
  • Smallpox
  • Tetanus
  • Tickborne encephalitis
  • Typhoid
  • Varicella (chickenpox)
  • Yellow fever

Diseases and infections with limited-use vaccines

  • Adenovirus types 4 and 7
  • Anthrax

Diseases and infections with no vaccines or only partially effective vaccines

  • Campylobacter
  • Cancer
  • Candida
  • Chikungunya
  • Chlamydia Moraxella
  • Clostridium difficile
  • Cryptosporidium
  • Cytomegalovirus
  • Dengue
  • Ebola and viral hemorrhagic fevers
  • Enterovirus including EV71, EV68, CA16
  • Epstein-Barr virus
  • Escherichia coli
  • Haemophilus influenzae, nontypable
  • Helicobacter
  • Helminths (numerous)
  • Hendra virus
  • Hepatitis type C
  • Hepatitis type E
  • Herpesvirus type 6
  • Herpes simplex
  • HIV/AIDS
  • Influenza, universal
  • Influenza, avian types H5 and H7
  • Leishmaniasis
  • Lyme disease
  • Malaria
  • MERS
  • Metapneumovirus
  • Moraxella (for otitis)
  • Neisseria gonorrhoeae
  • Nipah virus
  • Norovirus
  • Nosocomial bacteria
  • Parainfluenza
  • Plague
  • Rhinovirus
  • RSV
  • Salmonella paratyphi
  • SARS
  • Schistosomiasis
  • Shigella
  • Staphylococcus
  • Strep Group A
  • Strep Group B
  • Toxoplasmosis
  • Trypanosomiasis
  • Tuberculosis
  • West Nile virus

* Updated information is from the Foundation for Vaccine Research. Nipah and Hendra viruses were unintentionally omitted in the list published in NEJM. MERS denotes Middle East Respiratory Syndrome, RSV Respiratory Syncytial Virus, and SARS Severe Acute Respiratory Syndrome. Vaccines for some of the targets indicated above are in advanced development, but most are not.

28 January 2016

Zika virus added to list of priority targets for proposed fund

The spread of Zika virus in the Americas has become a major source of concern since its pathogenicity has become more clear. Particularly worrisome is the alarming jump in the reported number of cases of infant microcephaly in Brazil. Adding Zika virus and Paratyphoid A (Salmonella enterica) brings the list of priority targets to 17, in close alignment with WHO's list of dangerous pathogens put out on 12 December 2015.

Learn more about Zika virus

The Zika virus is a flavivirus, part of the same family as yellow fever, West Nile, chikungunya and dengue viruses. Like them, it is transmitted to humans via the bite of an infected Aedes sp. mosquito. But unlike some of those viruses, there is no vaccine to prevent Zika or medicine to treat the infection. Zika is commanding worldwide attention because of an alarming, suspected but not proven connection between infection with the virus and microcephaly, a neurological complication that results in babies being born with abnormally small heads. This causes severe developmental issues and sometimes death. Since November 2015, Brazil has reported 4,180 cases of microcephaly in babies born to women who were infected with Zika during their pregnancies, compared to only 146 cases in 2014. Authorities have not been able to confirm that all 4,180 cases are attributable to infection with the virus. So far, 51 babies have died. Until recently, the virus was considered relatively harmless. In 80% of cases, it causes no symptoms and people are unaware they have been infected. In 20% of cases, it causes Zika fever, a mild disease with symptoms including rash, joint pain and conjunctivitis. The Zika virus was first identified in Uganda in 1947. It was not until 2015 that a previously unknown connection between Zika infection in pregnant women and microcephaly in newborns was reported.

See WHO list of priority pathogens.

 

17 priority targets (updated January 28)

Same criteria as before (see note below). List modified to provide more detail on prioritization based on the latest information.

  • Ebola hemorrhagic fever virus
  • Lassa hemorrhagic fever virus
  • Marburg hemorrhagic fever virus
  • MERS coronavirus
  • SARS coronavirus
  • Crimean-Congo hemorrhagic fever virus
  • Chikungunya virus
  • Nipah virus
  • Hepatitis E virus
  • Zika virus
  • Enterovirus 71
  • Enterovirus 68
  • Coxsackievirus 16
  • Paratyphoid A (Salmonella enterica)
  • West Nile virus
  • Rift Valley fever virus
  • Plague (Yersinia pestis)

The criteria used for developing this updated list are unchanged. They include: case fatality rate; transmissibility and capacity for human-to-human transmission; frequency of outbreaks; geographical spread; existence of other interventions, investment, and development stage globally; and scientific feasibility of candidates.

Source: Working group

The Zika virus

20 January 2016

Vaccine development fund to be discussed at the World Economic Forum in Davos.

The proposed global vaccine development fund called for in The New England Journal of Medicine will be discussed at a high-level, 90-minute closed session at the Davos summit on 21 January. Moderated by Dr. Peter Piot, the session will be attended by 30 senior decision makers from governments, industry, foundations, WHO, MSF, and other stakeholders. The purpose of the meeting is to forge a broad consensus on the way forward in the development of the fund.

Davos prepares to discuss proposed fund.

12 January 2016

Leading vaccinologist endorses proposed fund

“In 1955, twenty-seven companies made vaccines. By 1980, due to drop out and merger, 18 vaccine makers remained. Today, only 4 major pharmaceutical companies focus on vaccines. This dramatic decline isn't because infectious diseases are now a thing of the past. Quite the opposite. Recent outbreaks of viral diseases like MERS-CoV, SARS, Ebola, West Nile, and chikungunya show that vaccines are needed now more than ever before. The problem is that the business model is geared to products with only a large market potential. Something needs to be done. Perhaps the single best solution would be the creation of a global vaccine development fund that would promote the development of vaccines that currently have fallen through the cracks. Without such a program, the continued erosion in vaccine research and development is inevitable.”

Paul Offit MD
Maurice R Hilleman Professor of Vaccinology
Co-inventor of the rotavirus vaccine
and Professor of Pediatrics
The Children's Hospital of Philadelphia

The Children's Hospital of Philadelphia

1 January 2016

Scientifically feasible vaccines against major diseases are stalled for lack of funds, says Science.

In a feature article entitled “Unfilled Vials,” the journal Science names 10 top candidate vaccines that need a boost. “Vaccines that appear scientifically feasible often move through development slowly because they have little commercial potential and thus have trouble attracting serious investments,” writes Jon Cohen, senior Science reporter who covers vaccines. “Just such a situation held back R&D on Ebola vaccines, one of which quickly proved its worth in a real-world trial held in Guinea last year. In the wake of that success, a growing number of researchers and public health advocates are lobbying to find new money and strategies to develop vaccines that could thwart both outbreak diseases like chikungunya and Marburg to endemic afflictions like paratyphoid fever and schistosomiasis. In the past few weeks, the WHO and the nonprofit Foundation for Vaccine Research have taken a stab at identifying what those vaccines are, and they’ve zeroed in on the exact same targets.

Cohen went on to describe in some detail the proposed $2 billion global vaccine development fund called for in The New England Journal of Medicine last July, noting that it is on the agenda to be discussed at the World Economic Forum in Davos, Switzerland, on 21 January.

Read the full article

See results of survey

Feature article in Science magazine

9 December 2015

Priority targets provisionally identified for proposed fund

Fifteen infections have been provisionally identified as priority targets for the fund. Criteria used include: case fatality rate; transmissibility and capacity for human-to-human transmission; frequency of outbreaks; geographical spread; existence of other interventions, investment, and development stage globally; and scientific feasibility of candidates.

 

15 priority targets

  • Hemorrhagic fever viruses (Ebola,* Marburg, Lassa)
  • SARS and MERS coronaviruses
  • Chikungunya virus
  • West Nile virus
  • Nipah virus
  • Hepatitis E virus
  • Enteroviruses (EV68, EV71 and CA16)
  • Crimean-Congo hemorrhagic fever
  • Rift Valley fever
  • Plague (Yersinia pestis)

*To support licensure of existing candidates against Ebola Zaire species and the development of less advanced, multivalent, next-generation vaccines protective against Zaire, Bundibugyo and Sudan Ebola viruses.

Note: The fund’s purpose is to accelerate vaccine development globally for new and emerging infections, as well as neglected diseases and infections endemic in developing countries for which there is low market potential. Considerable resources are already being employed developing vaccines for pandemic influenza, Respiratory Syncytial Virus (RSV), HIV, Tuberculosis, malaria and Dengue, all of which are top priorities but outside the scope of the proposed fund.

Source: Working group

Cluster of coronaviruses

24 November 2015

World needs to create a fund to help pay for vaccine development, say experts in The Guardian.

“There are many diseases, like Ebola, for which no vaccine has yet been developed and this is largely because there is very little incentive for companies or public institutions to undertake research and development. To overcome this challenge, the world needs to create a fund to help pay for the development and distribution of vaccines for this and many other emerging epidemics and infectious diseases.”

Peter Piot
Director, London School of Hygiene & Tropical Medicine
Co-discoverer of the Ebola virus in 1976 in Zaire (now Democratic Republic of the Congo)

Paul Stoffels
Chief scientific officer and worldwide chairman of Johnson & Johnson Pharmaceuticals group

Vaccine development is a lengthy, labor-intensive, multistep process

22 November 2015

Harvard-LSHTM panel recommends a global facility to finance, accelerate, and prioritise R&D.

An independent panel of 19 experts convened by the Harvard Global Health Institute and the London School of Hygiene & Tropical Medicine has issued a hard-hitting analysis of the global response to the 2014 Ebola outbreak in West Africa, published in The Lancet.

Among ten essential reforms, the panel recommends establishing a global facility to finance, accelerate, and prioritize research and development, citing the New England Journal of Medicine paper calling for establishing a global vaccine development fund.

See Recommendation 7 calling for establishing a global facility to finance and accelerate R&D.

See members of the panel.

Members of the Panel

Dr Suerie Moon, Harvard Global Health Institute/Harvard School of Public Health/Harvard Kennedy School (Study Director)

  • Professor Peter Piot, London School of Hygiene & Tropical Medicine (Chair)
  • Dr Ashish Jha, Harvard Global Health Institute/Harvard School of Public Health (Co-chair)
  • Dr Muhammad Pate,
    Duke University (Co-chair)
  • Dr Devi Sridhar,
    Edinburgh Medical School (Co-chair)
  • Dr Chelsea Clinton,
    Bill, Hillary & Chelsea Clinton Foundation
  • Ms Sophie Delaunay,
    Médecins Sans Frontières
  • Ms Valnora Edwin,
    Campaign for Good Governance
  • Dr Mosoka Fallah,
    Action Contre La Faim International (ACF)
  • Mr David Fidler,
    Indiana University Maurer School of Law
  • Dr Eric Goosby,
    University of California, San Francisco
  • Ms Laurie Garrett,
    Council on Foreign Relations
  • Dr Larry Gostin,
    Georgetown University
  • Dr David Heymann,
    Chatham House
  • Dr Kelley Lee,
    Simon Fraser University
  • Dr Gabriel Leung,
    The University of Hong Kong
  • Dr Steve Morrison,
    Center for Strategic and International Studies
  • Dr Jorge Saavedra,
    AIDS Healthcare Foundation
  • Dr Marcel Tanner,
    Swiss Tropical & Public Health Institute

See video recording of the event on 23 November 2015 when the findings were presented at the Royal Society, London.

close

Recommendation 7: Establish a global facility to finance, accelerate, and prioritise research and development

The UN Secretary General and WHO Director-General should convene in 2016 a high-level summit of public, private and not-for-profit research funders to establish a global financing facility for research and development for health technologies relevant for major disease outbreaks. The facility would support manufacturing, research and development for drugs, vaccines, diagnostics and other non-pharmaceutical supplies (such as personal protective equipment) where the commercial market does not offer appropriate incentives. For known pathogens, the facility could invest in bringing candidate drugs, vaccines, technology platforms, and other relevant products through proof of concept, phase 1 and phase 2 testing in humans, so that they are ready for wider testing, manufacturing, and distribution when an outbreak strikes. During an outbreak the fund would rapidly mobilise financing for priority research and development projects, such as diagnostics for novel pathogens.

The establishment of a similar fund for diseases affecting developing countries was a central recommendation of the 2012 report of the WHO Consultative Expert Working Group on research and development.1 As a result, a pooled international fund was created to support “demonstration projects” that test new research and development business models, such as open knowledge innovation and de-linkage of research and development financing from end product prices. With a management structure already established, the demonstration projects offer an important option for pursuing research and development for Ebola or other diseases.

The global financing facility should be a lean, efficient entity that mobilises and strategically deploys resources. It would not be a monolithic entity nor the sole funder for epidemic-related research and development because some pluralism and competition among funders is desirable. Nevertheless, a global facility would offer the advantage of facilitating coordination among different research funders through a common framework, strengthening networks between researchers, establishing processes for priority setting, and reducing transaction costs for both grantees and smaller donors.2,3 It could also require information sharing among researchers as a condition of funding, thereby giving teeth to the data-sharing framework (recommendation 6). Intellectual property or any other asset resulting from these investments should be managed as a public good to facilitate follow-on innovation, open knowledge sharing, access to technology and a fair public return on investment. Support for a global research and development financing mechanism now seems to be growing, as shown in calls for a $2 billion global fund for vaccine development for pandemics,2 a $2 billion global fund for antimicrobial resistance,4 and a $2-3 billion global fund that would cover emerging infectious diseases, neglected diseases and antimicrobial resistance.5

19 November 2015

World-renowned Institut Pasteur is first to endorse the proposed fund

“The Institut Pasteur has been at the forefront of the fight against many epidemics over the past century, most recently against Ebola. Research in vaccinology is at the heart of our legacy and we are significantly reinforcing our efforts in this area. The Institut Pasteur is pleased to support your most valuable efforts to set up a global vaccine development fund. The initiative you have launched is a most important progress for the control of infectious diseases; clearly, this is what should be implemented to meet with the next epidemics, worldwide.”

Professor Christian Bréchot
President, Institut Pasteur

The Institut Pasteur, Paris

15 November 2015

We're moving!

The Foundation will be moving over the Thanksgiving weekend from 1425 K Street NW into sparkling new offices in the Paramount Building at 1775 Eye Street NW in Washington, DC. Please note our new address. Our phone and fax numbers stay the same.

Entrance to the Paramount Building at 1775 Eye Street, Washington, DC

1 November 2015

Foundation hosts second planning meeting of the core group in Dublin

The FVR’s Board Chair Simon Wain-Hobson, Institut Pasteur, and FVR Director Adel Mahmoud, Princeton University, host a planning meeting of the core group driving the proposed vaccine development fund at the Westin Dublin Hotel. Held on the eve of the Princeton-Fung Global Forum 2015 on lessons learned from the Ebola crisis, this highly-productive meeting marked another milestone in the fund’s development with agreement on the need to set up an interim secretariat.

The Dublin meeting follows an inaugural meeting of the core group in a retreat-like setting hosted by Dr. Mahmoud at his home in Princeton on September 12-13. The group has since expanded from five to seven members.

See members of core group.

Global Vaccine Development Fund Working Group

  • Jeremy Farrar MD PhD
  • Tore Godal MD
  • Peter Hale
  • Adel AF Mahmoud MD PhD
  • Peter Piot MD PhD
  • Stanley A Plotkin MD
  • Simon Wain-Hobson DPhil

Contact: Peter Hale
c/o The Foundation for Vaccine Research
Office +1 202 587 2754
Mobile +1 202 297 7458
peter.hale@vaccinefoundation.org

The Westin Dublin Hotel

29-30 October 2015

Support for proposed fund grows in Oslo consultation

The FVR’s founder and executive director Peter Hale gives a talk on the proposed vaccine development fund in Oslo at a high-level consultation organized by the WHO and the Norwegian Institute of Public Health on financing for R&D preparedness. The outcome of the consultation will inform the development of a blueprint for accelerating R&D in future epidemics or public health emergencies.

See agenda
See slide presentation

Oslo City Hall and waterfront

21-22 September 2015

Proposed fund makes its debut at World Bank-WHO meeting in Washington

The FVR’s Stanley Plotkin makes the case for the proposed global vaccine development fund in a special session of the World Bank Group-WHO stakeholders meeting on pandemic financing at the World Bank in Washington.

World Bank Group Headquarters, Washington, DC

21 August 2015

Support builds for reform of vaccine development through proposed fund.

See editorial in The New York Times; see articles in The New York Times, The Wall Street Journal, The Guardian, Reuters, Business Insider, CIDRAP News, and Fierce Vaccines.

 

Global Dispatches Podcast

Interview with Dr. Jeremy Farrar, Professor of Tropical Medicine and Director of the Wellcome Trust, in which he discusses the implications of the recent Ebola vaccine trial and how the creation of a global vaccine development fund will spur the development and deployment of vaccines to counter fast emerging epidemics. (12:00)

Listen
Download